PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022
SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that Natasha Giordano, President and CEO of PLx Pharma Inc. and Rita O’Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on March 15, 2022, at Oppenheimer & Co’s 32nd Annual Healthcare Conference, which will be a virtual event this year.
Oppenheimer & Co’s 32nd Annual Healthcare Conference
| Date | Tuesday, March 15, 2022 |
| Time | 3:20 p.m. ET |
| Webcast (live and replay) | https://wsw.com/webcast/oppenheimer20/plxp/2818872 |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via PLx Pharma’s investor relations website at https://ir.plxpharma.com/events-presentations/events.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule is designed for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contacts:
Janet M. Barth
Vice President, Investor Relations & Corporate Communications, PLx Pharma Inc.
(973) 409-6542
IR@PLxPharma.com
Lisa M. Wilson
Founder & President, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
